Skip to main content
Top
Published in: Current Atherosclerosis Reports 8/2014

01-08-2014 | Nutrition (JP Foreyt, Section Editor)

Dietary Trans Fatty Acids and Cardiovascular Disease Risk: Past and Present

Author: Alice H. Lichtenstein

Published in: Current Atherosclerosis Reports | Issue 8/2014

Login to get access

Abstract

Dietary trans double bond containing fatty acids have been associated with increased risk of cardiovascular disease. There are two main sources of dietary trans fatty acids: meat and dairy fats, and partially hydrogenated fats. Because of a number of factors, including changes in federal labeling requirements for packaged foods, and local bans and grassroots pressure on the use of partially hydrogenated fat, trans fat intake has declined in recent years. Similar to saturated fatty acids, trans fatty acids increase plasma low density lipoprotein (LDL)-cholesterol concentrations. In contrast to saturated fatty acids, trans fatty acids do not increase high density lipoprotein (HDL)-cholesterol concentrations. These differences have been attributed to lipoprotein catabolic rate rather than production rate. When reported, effects of partially hydrogenated fat on glucose homeostasis, C-reactive protein, blood pressure, and LDL oxidation are modest. Although at this time some issues remain unresolved regarding trans fatty acids and CVD risk factors other than plasma lipoprotein concentrations, they should not affect the final dietary recommendation to limit intake.
Literature
1.
go back to reference Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135(1):1–7.PubMedCrossRef Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135(1):1–7.PubMedCrossRef
2.
go back to reference Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.PubMedCrossRef Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.PubMedCrossRef
4.
go back to reference Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCentralPubMedCrossRef Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCentralPubMedCrossRef
5.
go back to reference Baum SJ, Kris-Etherton P, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in acrdiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6:216–34.PubMedCrossRef Baum SJ, Kris-Etherton P, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in acrdiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6:216–34.PubMedCrossRef
6.
go back to reference Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol. 2004;24(6):1092–7. doi:10.1161/01.ATV.0000128410.23161.be.PubMedCrossRef Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol. 2004;24(6):1092–7. doi:10.​1161/​01.​ATV.​0000128410.​23161.​be.PubMedCrossRef
7.
go back to reference Eckel RH, Borra S, Lichtenstein AH, Yin-Piazza SY. Understanding the complexity of trans fatty acid reduction in the American diet. Circulation. 2007;115:2231–46.PubMedCrossRef Eckel RH, Borra S, Lichtenstein AH, Yin-Piazza SY. Understanding the complexity of trans fatty acid reduction in the American diet. Circulation. 2007;115:2231–46.PubMedCrossRef
8.
go back to reference Gebauer SK, Chardigny JM, Jakobsen MU, Lamarche B, Lock AL, Proctor SD, et al. Effects of ruminant trans fatty acids on cardiovascular disease and cancer: a comprehensive review of epidemiological, clinical, and mechanistic studies. Adv Nutr. 2011;2:332–54.PubMedCentralPubMedCrossRef Gebauer SK, Chardigny JM, Jakobsen MU, Lamarche B, Lock AL, Proctor SD, et al. Effects of ruminant trans fatty acids on cardiovascular disease and cancer: a comprehensive review of epidemiological, clinical, and mechanistic studies. Adv Nutr. 2011;2:332–54.PubMedCentralPubMedCrossRef
9.
go back to reference Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–13.PubMedCrossRef Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–13.PubMedCrossRef
10.
go back to reference Lefevre M, Mensink RP, Kris-Etherton PM, Petersen B, Smith K, Flickinger BD. Predicted changes in fatty acid intakes, plasma lipids, and cardiovascular disease risk following replacement of trans fatty acid-containing soybean oil with application-appropriate alternatives. Lipids. 2012;47(10):951–62. doi:10.1007/s11745-012-3705-y.PubMedCentralPubMedCrossRef Lefevre M, Mensink RP, Kris-Etherton PM, Petersen B, Smith K, Flickinger BD. Predicted changes in fatty acid intakes, plasma lipids, and cardiovascular disease risk following replacement of trans fatty acid-containing soybean oil with application-appropriate alternatives. Lipids. 2012;47(10):951–62. doi:10.​1007/​s11745-012-3705-y.PubMedCentralPubMedCrossRef
12.
go back to reference Doell D, Folmer H, Lee HR, Honigfort M, Carberry S. Updated esimtate of trans fat intake by the US population. Food Addit Contam. 2012;29:861–74.CrossRef Doell D, Folmer H, Lee HR, Honigfort M, Carberry S. Updated esimtate of trans fat intake by the US population. Food Addit Contam. 2012;29:861–74.CrossRef
13.
go back to reference Food and Drug Administration. Food labeling: trans fatty acids in nutrition labeling, nutrient content claims, and health claims. Final rule. Fed Regist. 2003;133:41433–14506. Food and Drug Administration. Food labeling: trans fatty acids in nutrition labeling, nutrient content claims, and health claims. Final rule. Fed Regist. 2003;133:41433–14506.
14.
go back to reference Rahkovsky I, Martinez S, Kuchler F. New food choices free of trans fats better align U.S. diets with health recommendations. Economic Information Bulletin Number 95, USDA. 2012. Rahkovsky I, Martinez S, Kuchler F. New food choices free of trans fats better align U.S. diets with health recommendations. Economic Information Bulletin Number 95, USDA. 2012.
16.•
go back to reference Angell SY, Cobb LK, Curis CJ, Konty KJ, Silver LD. Change in trans fatty acid content of fast food purchases associated with New York City's restaurant regulation. Annal of Internal Medicine. 2012. This study demonstrated that restricting the use of partially-hydrogenated fat in New York City dramatically decreased the mean trans fatty acid content of food purchased from fast-food restaurants. Angell SY, Cobb LK, Curis CJ, Konty KJ, Silver LD. Change in trans fatty acid content of fast food purchases associated with New York City's restaurant regulation. Annal of Internal Medicine. 2012. This study demonstrated that restricting the use of partially-hydrogenated fat in New York City dramatically decreased the mean trans fatty acid content of food purchased from fast-food restaurants.
17.
go back to reference Food and Drug Administration. FDA takes step to further reduce trans fats in processed foods. 2013. Food and Drug Administration. FDA takes step to further reduce trans fats in processed foods. 2013.
18.•
go back to reference Vesper HW, Kuiper HC, Mirel LB, Johnson CL, Pirkle JL. Levels of plasma trans-fatty acids in non-hispanic white adults in the United States in 2000 and 2009. JAMA. 2012;307:562. The findings of this study demonstrate that secular changes in the use of partially-hydrogenated fat in the food supply has an effect on a measurable biomarker, plasma trans fatty acid concentration.PubMedCrossRef Vesper HW, Kuiper HC, Mirel LB, Johnson CL, Pirkle JL. Levels of plasma trans-fatty acids in non-hispanic white adults in the United States in 2000 and 2009. JAMA. 2012;307:562. The findings of this study demonstrate that secular changes in the use of partially-hydrogenated fat in the food supply has an effect on a measurable biomarker, plasma trans fatty acid concentration.PubMedCrossRef
22.
go back to reference Temme EH, Millenaar IL, Van Donkersgoed G, Westenbrink S. Impact of fatty acid food reformulations on intake of Dutch young adults. Acta Cardiol. 2011;66:721–8.PubMed Temme EH, Millenaar IL, Van Donkersgoed G, Westenbrink S. Impact of fatty acid food reformulations on intake of Dutch young adults. Acta Cardiol. 2011;66:721–8.PubMed
23.
go back to reference Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146–55.PubMed Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146–55.PubMed
24.
go back to reference Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999;340(25):1994–8.PubMedCrossRef Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999;340(25):1994–8.PubMedCrossRef
25.
go back to reference Lichtenstein AH, Ausman LA, Jalbert SM, Schaefer EJ. Comparison of different forms of hydrogenated fats on serum lipid levels in moderately hypercholesterolemic female and male subjects. N Engl J Med. 1999;340:1933–40.PubMedCrossRef Lichtenstein AH, Ausman LA, Jalbert SM, Schaefer EJ. Comparison of different forms of hydrogenated fats on serum lipid levels in moderately hypercholesterolemic female and male subjects. N Engl J Med. 1999;340:1933–40.PubMedCrossRef
26.
go back to reference Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43(3):445–52.PubMed Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43(3):445–52.PubMed
27.
28.
go back to reference Aronis KN, Joseph RJ, Blackburn GL, Mantzoros C. Trans-fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials? Metab Clin Exp. 2011;60(7):901–5. doi:10.1016/j.metabol.2011.04.003.PubMedCrossRef Aronis KN, Joseph RJ, Blackburn GL, Mantzoros C. Trans-fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials? Metab Clin Exp. 2011;60(7):901–5. doi:10.​1016/​j.​metabol.​2011.​04.​003.PubMedCrossRef
29.
go back to reference Bendsen NT, Christensen R, Bartels EM, Astrup A. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr. 2011;65:773–83.PubMedCrossRef Bendsen NT, Christensen R, Bartels EM, Astrup A. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr. 2011;65:773–83.PubMedCrossRef
31.
go back to reference Matthan NR, Ausman LM, Lichtenstein AH, Jones PJ. Hydrogenated fat consumption affects cholesterol synthesis in moderately hypercholesterolemic women. J Lipid Res. 2000;41(5):834–9.PubMed Matthan NR, Ausman LM, Lichtenstein AH, Jones PJ. Hydrogenated fat consumption affects cholesterol synthesis in moderately hypercholesterolemic women. J Lipid Res. 2000;41(5):834–9.PubMed
32.
go back to reference Cuchel M, Schwab US, Jones PJ, Vogel S, Lammi-Keefe C, Li Z, et al. Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low-density lipoprotein to oxidation in moderately hypercholesterolemic individuals. Metab Clin Exp. 1996;45(2):241–7.PubMedCrossRef Cuchel M, Schwab US, Jones PJ, Vogel S, Lammi-Keefe C, Li Z, et al. Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low-density lipoprotein to oxidation in moderately hypercholesterolemic individuals. Metab Clin Exp. 1996;45(2):241–7.PubMedCrossRef
33.
go back to reference Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, et al. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res. 2001;42(4):597–604.PubMed Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, et al. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res. 2001;42(4):597–604.PubMed
35.
go back to reference Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003;78(3):370–5.PubMed Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003;78(3):370–5.PubMed
36.
go back to reference Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171(1):97–107.PubMedCrossRef Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171(1):97–107.PubMedCrossRef
38.
go back to reference Matthan NR, Cianflone K, Lichtenstein AH, Ausman LM, Jauhiainen M, Jones PJ. Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res. 2001;42(11):1841–8.PubMed Matthan NR, Cianflone K, Lichtenstein AH, Ausman LM, Jauhiainen M, Jones PJ. Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res. 2001;42(11):1841–8.PubMed
39.
go back to reference Booth SL, Davidson KW, Lichtenstein AH, Sadowski JA. Plasma concentrations of dihydro-vitamin K1 following dietary intake of a hydrogenated vitamin K1-rich vegetable oil. Lipids. 1996;31(7):709–13.PubMedCrossRef Booth SL, Davidson KW, Lichtenstein AH, Sadowski JA. Plasma concentrations of dihydro-vitamin K1 following dietary intake of a hydrogenated vitamin K1-rich vegetable oil. Lipids. 1996;31(7):709–13.PubMedCrossRef
40.
go back to reference Erkkila AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr. 2005;59:196–204.PubMedCrossRef Erkkila AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr. 2005;59:196–204.PubMedCrossRef
41.
go back to reference Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, Wilson PW, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr. 2005;93(5):701–8.PubMedCrossRef Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, Wilson PW, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr. 2005;93(5):701–8.PubMedCrossRef
42.
go back to reference de Roos B, Wanders AJ, Wood S, Horgan G, Rucklige G, Reid M, et al. A high intake of industrial or ruminant trans fatty acids does not affect the plasma proteome in healthy men. Proteomics. 2011;11(19):3928–34. doi:10.1002/pmic.201100163.PubMedCrossRef de Roos B, Wanders AJ, Wood S, Horgan G, Rucklige G, Reid M, et al. A high intake of industrial or ruminant trans fatty acids does not affect the plasma proteome in healthy men. Proteomics. 2011;11(19):3928–34. doi:10.​1002/​pmic.​201100163.PubMedCrossRef
43.
44.
go back to reference Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323(7):439–45.PubMedCrossRef Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323(7):439–45.PubMedCrossRef
49.•
go back to reference Kiage JN, Merrill PD, Robinson CJ, Cao Y, Malik TA, Hundley BC, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(5):1121–8. doi:10.3945/ajcn.112.049064. The data from this study indicated that in a racially and ethnically diverse group of individuals living in the U.S. higher trans fat intake was associated with an increased risk of all-cause mortality.PubMedCentralPubMedCrossRef Kiage JN, Merrill PD, Robinson CJ, Cao Y, Malik TA, Hundley BC, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(5):1121–8. doi:10.​3945/​ajcn.​112.​049064. The data from this study indicated that in a racially and ethnically diverse group of individuals living in the U.S. higher trans fat intake was associated with an increased risk of all-cause mortality.PubMedCentralPubMedCrossRef
50.
go back to reference Brouwer IA, Wanders AJ, Katan BM. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans–a quantitative review. PLoS One. 2010;5:e9434.PubMedCentralPubMedCrossRef Brouwer IA, Wanders AJ, Katan BM. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans–a quantitative review. PLoS One. 2010;5:e9434.PubMedCentralPubMedCrossRef
51.
go back to reference Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman AS, Tverdal A, et al. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr. 2012;108(4):743–54. doi:10.1017/S0007114511005897.PubMedCrossRef Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman AS, Tverdal A, et al. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr. 2012;108(4):743–54. doi:10.​1017/​S000711451100589​7.PubMedCrossRef
53.
go back to reference Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, et al. AHA/acc guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1161/01.cir.0000437740.48606.d1. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, et al. AHA/acc guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.​1161/​01.​cir.​0000437740.​48606.​d1.
54.
go back to reference Lichtenstein AH. New York City trans fat ban: improving the default option when purchasing foods prepared outside of the home. Annal Intern Med. 2012;157:144–5.CrossRef Lichtenstein AH. New York City trans fat ban: improving the default option when purchasing foods prepared outside of the home. Annal Intern Med. 2012;157:144–5.CrossRef
Metadata
Title
Dietary Trans Fatty Acids and Cardiovascular Disease Risk: Past and Present
Author
Alice H. Lichtenstein
Publication date
01-08-2014
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 8/2014
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0433-1

Other articles of this Issue 8/2014

Current Atherosclerosis Reports 8/2014 Go to the issue

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

Thrombus Aspiration in Primary Angioplasty for ST-segment Elevation Myocardial Infarction

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

HDL: To Treat or Not To Treat?

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

New Risk Markers for Cardiovascular Prevention

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.